US to no longer distribute Eli Lilly’s bamlanivimab alone due to coronavirus variants
The US government and Eli Lilly agreed to halt all distribution of the company’s Covid-19 monoclonal antibody bamlanivimab as of Wednesday due to the “sustained increase” of coronavirus variants in the US.
All treatment delivery sites will continue to be able to order Lilly’s combo Covid-19 treatment of bamlanivimab and etesevimab, to be administered together, or Regeneron’s antibody cocktail, the assistant secretary for preparedness and response (ASPR) and FDA said. Both of the treatments from Lilly and Regeneron have proven to be useful among people who have Covid-19 but are not hospitalized.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.